Nacuity Pharmaceuticals
Fort Worth, US · Founded 2016 · Delaware corporation · 1 known investors
Nacuity develops targeted therapies aimed at stopping oxidative tissue damage, a driver of blinding eye diseases and other chronic conditions. Its clinical programs address retinitis pigmentosa, cataract, and cystinosis.
BiotechHealthtechMedical Devices
Founders & leadership
MW
Michael WallExecutive
DW
David WohlbergExecutive
JK
Jami KernExecutive
HC
Halden ConnerExecutive
CL
Charles LieserExecutive
Board
EC
Emmett Cunningham, Jr.Board director
RS
Robin SteeleBoard director
RK
Rusty KelleyBoard director
GC
Gerald CagleBoard director
BY
Benjamin YerxaBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$31.2M disclosed across 4 rounds · 2016–2025
▶$8.4MraisedDec 2025 · 98 investors · PharmaceuticalsRule 506(b)
▶$8.4MraisedDec 2025 · 98 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael WallExecutive Officer
- Robin SteeleDirector
- David WohlbergExecutive Officer, Director
- Rusty KelleyDirector
- Gerald CagleDirector
- Jami KernExecutive Officer
- Benjamin YerxaDirector
- Emmett Cunningham, Jr.Director
- Halden ConnerExecutive Officer, Director
- Charles LieserExecutive Officer
- Offering amount
- $30M
- Amount sold
- $8.4M
- Minimum investment
- $9.4K
- Sales commissions
- $839.3K
- Placement agents
- Maxim Group LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.6MraisedJan 2022 · 144 investors · BiotechnologyRule 506(b)
▶$11.6MraisedJan 2022 · 144 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David WohlbergExecutive Officer, Director
- Charles LieserExecutive Officer
- Halden ConnerExecutive Officer, Director
- Robert RuffoloDirector
- Robin SteelDirector
- Benjamin YerxaDirector
- Gerald CagleDirector
- Offering amount
- $17.4M
- Amount sold
- $11.6M
- Minimum investment
- $10K
- Sales commissions
- $1.4M
- Placement agents
- Clifford Adam Teller
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.2MraisedJul 2017 · 125 investors · BiotechnologyRule 506(b)
▶$9.2MraisedJul 2017 · 125 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac BlechDirector
- Charles LieserExecutive Officer
- G. Michael Wall, Ph.D.Executive Officer
- Dr. Gerald D. CagleDirector
- David J. WohlbergDirector
- William Halden ConnerExecutive Officer, Director
- Richard Chin, M.D.Director
- Sanford HillsbergDirector
- Offering amount
- $10M
- Amount sold
- $9.2M
- Minimum investment
- $25K
- Sales commissions
- $922.7K
- Placement agents
- Clifford Adam Teller
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$2MraisedDec 2016 · 46 investors · PharmaceuticalsRule 506(b)
▶$2MraisedDec 2016 · 46 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- William Halden ConnerExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2M
- Minimum investment
- $10K
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Nacuity Pharmaceuticals do?
- Nacuity develops targeted therapies aimed at stopping oxidative tissue damage, a driver of blinding eye diseases and other chronic conditions. Its clinical programs address retinitis pigmentosa, cataract, and cystinosis.
- Who are Nacuity Pharmaceuticals's investors?
- Nacuity Pharmaceuticals's investors include Tarnagulla Ventures.
- How much funding has Nacuity Pharmaceuticals raised?
- Nacuity Pharmaceuticals has disclosed $31.2M raised across 4 rounds.
- Where is Nacuity Pharmaceuticals headquartered?
- Nacuity Pharmaceuticals is headquartered in Fort Worth, US.